The work, led by Shearer, Antonson, Van Steenwinckel and colleagues, focuses on a problem that has complicated neonatal neuroscience for decades. Perinatal brain injury—including damage associated with oxygen deprivation, inflammation, infection or disrupted blood flow—cannot be studied in humans with the same experimental precision available in animals. Mice are widely used because they are practical and genetically tractable, while larger animals can more closely resemble human brain development in certain respects. Yet similarities in anatomy do not automatically mean that immune cells are at the same developmental stage.

Microglia are central to this challenge. Often described as the brain’s immune sentinels, they constantly survey neural tissue, remove damaged material and help shape connections between neurons. During early development, however, microglia are not simply defensive cells waiting for injury. They participate in the formation and refinement of neural circuits, regulate inflammatory signals, influence the survival of immature cells and help coordinate the transition from a developing to a mature nervous system. Their behavior therefore depends strongly on age and developmental context.

The new reference aims to make that context visible. Rather than treating “newborn,” “infant” or “juvenile” as interchangeable labels across species, the study examines microglial maturation as a biological process that can be compared across human and mouse development and then used to interpret large-animal models. This distinction is crucial because the same chronological age can represent very different stages of brain maturation in different species. A mouse that is described as neonatal may not possess microglia operating in a state equivalent to those in a human newborn.

At the cellular level, maturation can involve changes in morphology, gene activity, surface markers, metabolism and responses to environmental signals. Immature microglia may display molecular programs associated with construction and growth, while later stages are increasingly linked to surveillance, maintenance and coordinated responses to damage. After an injury, these programs can shift again. Cells may become activated, alter their shape, change their gene expression and release signaling molecules that affect neurons, blood vessels and other glial cells. Interpreting such changes requires knowing whether they reflect injury—or simply normal development.

That issue has direct consequences for translational research. An experimental treatment may appear to reduce inflammation in a mouse model while acting on a developmental pathway that is not dominant in human infants. Conversely, a response that looks excessive in an animal may represent a normal stage of immune maturation rather than pathological activation. By placing microglial states on a cross-species developmental map, the researchers seek to reduce these mismatches and help investigators select models whose biology is aligned with the human condition being studied.

Large-animal models are particularly important because their brains, body sizes, gestational patterns and postnatal development can provide intermediate or complementary perspectives between rodents and people. They are also more suitable for some forms of imaging, monitoring and clinically relevant intervention. But their value depends on careful biological benchmarking. The study’s framework is designed to help researchers ask a more precise question than whether an animal is simply “similar” to a human: which aspects of microglial maturation are shared, which are different and at what developmental point do those differences matter most?

The implications extend beyond perinatal brain injury. Microglial development is increasingly linked to neurodevelopmental disorders, epilepsy, white-matter damage and later-life neurological disease. A clearer understanding of how these cells mature could improve the interpretation of early inflammatory signals and reveal why the timing of an insult often matters as much as its severity. It may also support more rational testing of therapies intended to control harmful inflammation without blocking the beneficial immune functions needed for repair and brain development.

The study does not eliminate the complexity of translating animal research into clinical care, but it offers a practical foundation for doing so more intelligently. Its central message is that developmental biology must be treated as a measurement, not an assumption. As neonatal medicine searches for treatments that protect the vulnerable brain, comparing microglia across species may provide the biological “translation key” needed to distinguish a promising model from a misleading one. The resulting reference could become an important resource for researchers investigating how early-life injury reshapes the brain—and how those changes might be prevented.

Subject of Research: Comparative maturation of microglia in humans and mice, with implications for interpreting large-animal models of perinatal brain injury.

Article Title: Microglial maturation across human and mouse as a reference for interpreting large-animal models of perinatal brain injury

Article References: Shearer, I.K., Antonson, A., Van Steenwinckel, J. et al. “Microglial maturation across human and mouse as a reference for interpreting large-animal models of perinatal brain injury.” Pediatric Research (2026). https://doi.org/10.1038/s41390-026-05355-z

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05355-z

Keywords: microglia, brain development, perinatal brain injury, neuroinflammation, human-mouse comparison, large-animal models, neonatal neuroscience, translational medicine, pediatric research

For years, preclinical studies relying on mouse models have dominated STING research, driving the exploration of agonists that can potentiate the immune system’s attack on tumors. However, these models have consistently failed to fully translate into effective human therapies, in part due to fundamental species-specific differences in STING structure and function. The study published in Nature Chemical Biology meticulously dissects these differences, revealing a critical obstacle in the development of STING inhibitors that are effective in human cells. Specifically, the most advanced human STING inhibitor, H-151, though promising in murine systems for reversing neurodegeneration, fails to inhibit human STING in isolated human blood cells.

The crux of the problem lies in a subtle but pivotal structural divergence: the binding pocket targeted by H-151 in the mouse STING protein is absent in its human counterpart. This absence negates the inhibitor’s ability to form a stable, irreversible bond, which is essential for its potency in inhibiting immune activation. Li’s team elucidated how this mechanistic discrepancy substantially undermines the therapeutic potential of current inhibitors when applied to human patients. This revelation underscores the limitations of over-relying on animal models and highlights the imperative to tailor drug development strategies explicitly for human biology.

Diving deeper into the molecular choreography of STING activation, the researchers discovered that the process of oligomerization — where individual STING molecules aggregate into large, functional complexes — is indispensable for triggering downstream immune responses in humans. This step serves as a crucial checkpoint; the protein’s assembly must be precisely controlled to avoid inappropriate activation, which could otherwise provoke autoimmune pathology. Li’s lab identified that autoinhibitory mechanisms intrinsic to the human STING protein naturally prevent premature oligomerization, suggesting a potential therapeutic leverage point.

Taking inspiration from this built-in regulatory feature, the team engineered a proof-of-concept molecular inhibitor designed to prevent STING oligomerization directly, thereby blocking the pathway’s activation upstream. This approach diverges fundamentally from previous inhibitor designs that targeted the absent pocket, instead focusing on a conserved functional process that governs STING’s ability to signal. By mimicking STING’s own autoinhibitory strategy, the newly designed molecule effectively hinders the formation of oligomeric complexes, offering a novel angle for human-specific STING modulation.

The implications of this discovery are profound. As the first author Xujun Cao, a postdoctoral fellow in the Li Lab, explains, this refined understanding enables researchers to pinpoint “context-independent” drug targets, essentially those that remain effective regardless of variable cellular environments or species differences. It charts a route toward developing therapeutics that not only prevent STING overactivation linked to autoinflammatory and autoimmune diseases but also provide a safer, more precise modality for cancer immunotherapy.

Rebecca Chan, another lead author, elaborates on the biological significance of STING’s stringent regulation: “STING requires flawless oligomerization to function,” she states. This high activation threshold is vital because it prevents the immune system from turning against the host, a process that would otherwise result in widespread inflammation or tissue damage. The inherent tight control governing STING activity reveals the delicate balance the immune response must maintain between protective immunity and autoimmunity.

This study’s novel focus on inhibiting the pathway, rather than solely activating it, signifies a paradigm shift in STING-centered therapeutic strategies. Overactivation of STING has been increasingly associated with detrimental immune reactions, including autoimmune disorders and neurodegenerative diseases. Consequently, effective inhibitors tailored to human STING could revolutionize treatment paradigms across a spectrum of conditions where unwarranted inflammation is pathogenic.

Beyond oncology, the Li lab is intent on exploring how these insights might extend into neurodegeneration and autoimmunity. Given the complex role of immune signaling in brain health and systemic immune regulation, honing human-specific STING inhibitors could open new frontiers in combating diseases such as Alzheimer’s and systemic lupus erythematosus. The lab is concurrently advancing the molecular candidates identified to be “human-ready” for progression toward clinical trials, aiming to translate these molecular innovations from bench to bedside.

This meticulous dissection of human STING functionality and the subsequent design of innovative inhibitors illustrate a broader challenge in modern biomedical research: the essential need to integrate species-specific biological nuances into therapeutic design. It cautions against the blind adoption of animal model data and emphasizes precision-driven approaches that consider the unique molecular landscapes of human targets. Such strategies promise to enhance the efficacy, safety, and translational potential of immunomodulatory drugs.

Furthermore, this work benefits from interdisciplinary collaboration across biochemistry, molecular biology, and chemical biology, demonstrating how cross-cutting expertise can fuel transformative scientific breakthroughs. The Arc Institute’s unfettered research model, characterized by curiosity-driven yet goal-oriented inquiry, underscores the value of fostering environments where innovative ideas can flourish without conventional constraints.

As the quest to tame the immune system’s power continues, studies like this highlight the critical interplay between fundamental molecular discoveries and their implications for medicine. Unlocking the secrets of STING’s regulation in human cells not only enriches our understanding of innate immunity but also fuels the development of next-generation therapeutics poised to tackle some of medicine’s most intractable challenges.

Subject of Research: Cells
Article Title: Cysteine allostery and autoinhibition govern human STING oligomer functionality
News Publication Date: 3-Jul-2025
Web References: http://dx.doi.org/10.1038/s41589-025-01951-y
References: Chan, R., Cao, X., Ergun, S. L., Njomen, E., Lynch, S. R., Ritchie, C., Cravatt, B., & Li, L. (2025). Cysteine allostery and autoinhibition govern human STING oligomer functionality. Nature Chemical Biology.
Image Credits: Arc Institute

Keywords

Cancer, Chemical biology, Molecular biology, Cell biology, Cancer cells